Price movement over the last 24 hours
Align Technology, Inc. vs Koninklijke Philips NV — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while Koninklijke Philips NV trades at $27.4 (market cap $26.63B). The key difference: Koninklijke Philips NV is far larger — about 2.1× Align Technology, Inc.'s market cap, and Koninklijke Philips NV pays a 3.7% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ALGN | PHG | |
|---|---|---|
Market Cap | $12.86B | $26.63B |
Sector | Health | Health |
52-Week High | $207.19 | $32.91 |
52-Week Low | $124.88 | $24.03 |
Enterprise Value | $11.92B | $32.90B |
Dividend Yield | — | 3.7% |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
Royal Philips (PHG) trades at $27.40, up 0.51% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight growth initiatives. Analyst consensus leans neutral with 40.9% buy ratings amid stable revenue around $17.8 billion.
PHG presents a recovery story with margin expansion and AI innovation driving upside potential, though execution risks and debt levels near 25% of assets warrant caution. The stock's 24.1 P/E appears reasonable if earnings growth sustains, but investors should monitor competitive pressures in healthcare technology and macroeconomic impacts on capital spending.
Trailing returns across standard periods
Latest headlines on both assets
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →